Helix BioPharma Corp. (HBP.TO)
| Previous Close | 0.5500 |
| Open | 0.5300 |
| Bid | 0.5100 x 0 |
| Ask | 0.5400 x 0 |
| Day's Range | 0.5100 - 0.5400 |
| 52 Week Range | 0.2500 - 1.1600 |
| Volume | 6,016 |
| Avg. Volume | 10,430 |
| Market Cap | 76.212M |
| Beta (5Y Monthly) | -0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0550 |
| Earnings Date | Mar. 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.10 |
- ACCESSWIRE
Helix BioPharma Corp. Announces Delay of Annual Filings
RICHMOND HILL, ON / ACCESSWIRE / October 15, 2021 / Helix BioPharma Corp.In light of the Company's recent change of auditor, previously announced on June 24, 2021 and the departure of the Company's long tenured CEO & CSO effective September 1, 2021, in order to ensure that all internal and audit controls are properly executed, the Company has determined that it will not be able to complete the audit and file the Annual Filings by the Filing Deadline.
- ACCESSWIRE
Helix BioPharma Corp. Announces Appointment of Interim Chief Executive Officer
RICHMOND HILL, ON / ACCESSWIRE / September 20, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company's Chairman of the Board, Prof.
- ACCESSWIRE
Helix BioPharma Corp. Announces Appointment of New Director
RICHMOND HILL, ON / ACCESSWIRE / August 19, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr.
